Latest Breaking News On - Pyxis oncology - Page 5 : comparemela.com

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s.

Boston
Massachusetts
United-states
Laras-sullivan
Pamela-connealy
Apexigen-inc
Nasdaq
Company-annual-report-on-form
Linkedin
Pyxis-oncology-inc
Twitter
Novartis

Pyxis Oncology (PYXS) Announces 10.46M Share Offering by Selling Stockholders

Pyxis Oncology (PYXS) Announces 10.46M Share Offering by Selling Stockholders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Pyxis-oncology

Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research note released on Friday morning, Benzinga reports. The firm currently has a $7.00 price objective on the stock. PYXS has been the topic of several other reports. Leerink Partnrs reissued an outperform rating on shares […]

Blackrock
Nova-scotia
Canada
Leerink-partnrs
Blackrock-inc
Vanguard-group-inc
Royal-bank
Pyxis-oncology-inc
Citadel-advisors
Pyxis-oncology
Free-report
Get-free-report

HC Wainwright Increases Pyxis Oncology (NASDAQ:PYXS) Price Target to $7.00

Pyxis Oncology (NASDAQ:PYXS – Free Report) had its price target upped by HC Wainwright from $4.00 to $7.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock. Other equities research analysts have also issued reports about the company. BTIG Research began coverage […]

Leerink-partnrs
Blackrock-inc
Vanguard-group-inc
York-mellon-corp
Citigroup-inc
Pyxis-oncology-inc
Pyxis-oncology
Free-report
Oncology-trading-down
New-york-mellon-corp
State-street-corp
Street-corp

HC Wainwright Boosts Pyxis Oncology (NASDAQ:PYXS) Price Target to $7.00

Pyxis Oncology (NASDAQ:PYXS – Free Report) had its target price boosted by HC Wainwright from $4.00 to $7.00 in a report issued on Friday morning, Benzinga reports. They currently have a buy rating on the stock. Several other research firms also recently commented on PYXS. BTIG Research started coverage on Pyxis Oncology in a report […]

Leerink-partnrs
Prelude-capital-management
Commonwealth-equity-services
Pyxis-oncology-company-profile
Pyxis-oncology-inc
Acadian-asset-management
Pyxis-oncology
Free-report
Capital-management
Asset-management
Investment-advisers
Equity-services